Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Adjuvant Therapy
Interventions: DRUG: Pyrotinib+Trastuzumab+Capecitabine|DRUG: Trastuzumab+Pertuzumab/Trastuzumab
Sponsor: Fujian Medical University Union Hospital